Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

[1]  C. Meyer,et al.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.

[2]  K. Jang,et al.  Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas , 2013, PloS one.

[3]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[4]  B. Zhang,et al.  Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients , 2013, Cancer Immunology, Immunotherapy.

[5]  L. Terracciano,et al.  Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. , 2013, European journal of cancer.

[6]  Luciane T. Kagohara,et al.  PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival , 2013, Cancer Immunology Research.

[7]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[8]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[9]  N. Ditsch,et al.  Analysis of Epithelial Growth Factor-Receptor (EGFR) Phosphorylation in Uterine Smooth Muscle Tumors: Correlation to Mucin-1 and Galectin-3 Expression , 2013, International journal of molecular sciences.

[10]  R. Kiessling,et al.  Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients , 2012, Oncoimmunology.

[11]  H. Boezen,et al.  Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. , 2012, Gynecologic oncology.

[12]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[13]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[14]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[15]  B. Robinson,et al.  Programmed Death Ligand 2 in Cancer-Induced Immune Suppression , 2012, Clinical & developmental immunology.

[16]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[17]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[18]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[19]  O. Zekioğlu,et al.  Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival , 2011, Archives of Gynecology and Obstetrics.

[20]  Xueying Sun,et al.  The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival , 2011, Clinical & developmental immunology.

[21]  C. Mu,et al.  High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation , 2011, Medical oncology.

[22]  H. Yao,et al.  B7-H4 expression in various tumors determined using a novel developed monoclonal antibody , 2011, Clinical and Experimental Medicine.

[23]  Jeong-Won Lee,et al.  Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma , 2011, International Journal of Clinical Oncology.

[24]  N. Ditsch,et al.  Expression of mucin-1, galectin-1 and galectin-3 in human leiomyosarcoma in comparison to leiomyoma and myometrium. , 2011, Anticancer research.

[25]  P. Courtoy,et al.  A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. , 2010, Cancer research.

[26]  Yan Zhang,et al.  Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer , 2010, Cellular and Molecular Immunology.

[27]  D. Gabrilovich,et al.  Myeloid-Derived Suppressor Cells in Human Cancer , 2010, Cancer journal.

[28]  T. Okazaki,et al.  Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma , 2010, Cancer.

[29]  S. H. van der Burg,et al.  Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma , 2009, Clinical Cancer Research.

[30]  M. Munder.  Arginase: an emerging key player in the mammalian immune system , 2009, British journal of pharmacology.

[31]  Pieter Wesseling,et al.  Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. , 2009, Neuro-oncology.

[32]  D. Demydenko,et al.  Expression of galectin-1 in malignant tumors. , 2009, Experimental oncology.

[33]  Lieping Chen,et al.  Fine tuning the immune response through B7‐H3 and B7‐H4 , 2009, Immunological reviews.

[34]  M. Atkins,et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.

[35]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[36]  E. Diamandis,et al.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel , 2008, British Journal of Cancer.

[37]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[38]  G. Prendergast.  Immune escape as a fundamental trait of cancer: focus on IDO , 2008, Oncogene.

[39]  G. Rabinovich,et al.  Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.

[40]  H. Kajiyama,et al.  Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival , 2008, Clinical Cancer Research.

[41]  G. Zhu,et al.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.

[42]  D. Katsaros,et al.  B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. , 2007, Gynecologic oncology.

[43]  Ioannis Mylonas,et al.  Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. , 2007, Anticancer research.

[44]  K. Shroyer,et al.  B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. , 2007, Gynecologic oncology.

[45]  Haidong Dong,et al.  PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.

[46]  L. Lacombe,et al.  879: PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata: Associations with Localized Stage Progression , 2007 .

[47]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[48]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[49]  H. Kajiyama,et al.  Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer , 2006, British Journal of Cancer.

[50]  Gefeng Zhu,et al.  B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma , 2006, The Journal of experimental medicine.

[51]  N. Yanaihara,et al.  Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells , 2005, Clinical Cancer Research.

[52]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[53]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[54]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[55]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[56]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[57]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[58]  A. Berchuck,et al.  Galectin-1 Accumulation in the Ovary Carcinoma Peritumoral Stroma Is Induced by Ovary Carcinoma Cells and Affects Both Cancer Cell Proliferation and Adhesion to Laminin-1 and Fibronectin , 2003, Laboratory Investigation.

[59]  R. Kiss,et al.  Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors. , 1999, American journal of clinical pathology.

[60]  G. Benvenuto,et al.  Galectin‐1 and galectin‐3 expression in human bladder transitional‐cell carcinomas , 1999, International journal of cancer.

[61]  R. Bast,et al.  Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. , 1996, Human pathology.

[62]  D. Munn.  Blocking IDO activity to enhance anti-tumor immunity. , 2012, Frontiers in bioscience.

[63]  R. Kiss,et al.  The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. , 2008, Oral oncology.

[64]  S. Naudé,et al.  Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues. , 2003, Pathology, research and practice.

[65]  O. Takikawa,et al.  Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. , 2003, Advances in experimental medicine and biology.